Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 30, 2019Chemical Biology & Drug Design

Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

STSona TalaeiUniversity of MaraghehHMHassan MellatyarUniversity of MaraghehAAAsadollah AsadiUniversity of Mohaghegh Ardabili

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Talaei et al. (2019) studied this question.

synapsesocial.com/papers/6a207b43cbc595e190318335https://doi.org/10.1111/cbdd.13486
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer2007 · 214 citations
  2. 2Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies2005 · 491 citations
  3. 3Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers2005 · 194 citations
  4. 4MEK Inhibition Potentiates the Activity of Hsp90 Inhibitor 17-AAG against Pancreatic Cancer Cells2010 · 14 citations